# Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

Study · id `cardio:ct-nct05485961` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05485961](<https://clinicaltrials.gov/study/NCT05485961>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05485961

Browse, organ or system: Heart; Blood vessels; Kidneys  
Browse, condition area: Coronary and vascular disease; Kidney connections; Acute care and long-term living  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 3110 participants.

## Technical summary

Registry record NCT05485961. Randomized; quadruple masking; primary purpose supportive care. Start 2024-04-27 (actual); primary completion 2029-05-22 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose supportive care
- Phase: Phase 2/3
- Enrolled: 3110 participants (planned count; ClinicalTrials.gov record NCT05485961, source copy `cardio:ctgov-nct05485961-2026-09-21`, retrieved 2026-10-26)
- Started: 2024-04-27 (actual) (ClinicalTrials.gov record NCT05485961, source copy `cardio:ctgov-nct05485961-2026-09-21`, retrieved 2026-10-26)
- Primary completion: 2029-05-22 (anticipated) (ClinicalTrials.gov record NCT05485961, source copy `cardio:ctgov-nct05485961-2026-09-21`, retrieved 2026-10-26)
- Completion: 2029-05-22 (anticipated) (ClinicalTrials.gov record NCT05485961, source copy `cardio:ctgov-nct05485961-2026-09-21`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; China; Czechia; Denmark; France; Germany; Greece; Hong Kong SAR China; Hungary; Israel; Italy; Japan; Malaysia; Mexico; Netherlands; Norway; Poland; Portugal; Puerto Rico; Romania; Slovakia; South Korea; Spain; Sweden; Taiwan; Thailand; Türkiye; United Kingdom (ClinicalTrials.gov record NCT05485961, source copy `cardio:ctgov-nct05485961-2026-09-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05485961-2026-09-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
- Acronym: POSIBIL6ESKD
- Condition: End Stage Kidney Disease
- Intervention (Drug): CSL300
- Intervention (Drug): Placebo
- Lead sponsor: CSL Behring
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: Peripheral artery disease (`cardio:peripheral-artery-disease`)
- Registry lists this organization as the lead sponsor: CSL Behring (`cardio:org-csl-behring`)

## Provenance

Content hash: de423c8e78f1a189cbf6d1fd321eb974ee0af7cd147c64f9d915d7b2905fddca
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
